CH636888A5 - Heparines purifiees et leur preparation. - Google Patents
Heparines purifiees et leur preparation. Download PDFInfo
- Publication number
- CH636888A5 CH636888A5 CH841878A CH841878A CH636888A5 CH 636888 A5 CH636888 A5 CH 636888A5 CH 841878 A CH841878 A CH 841878A CH 841878 A CH841878 A CH 841878A CH 636888 A5 CH636888 A5 CH 636888A5
- Authority
- CH
- Switzerland
- Prior art keywords
- heparin
- salt
- oxalates
- salts
- metal
- Prior art date
Links
- 229920000669 heparin Polymers 0.000 title claims description 159
- 229960002897 heparin Drugs 0.000 title claims description 114
- 238000002360 preparation method Methods 0.000 title description 21
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 150
- 239000000243 solution Substances 0.000 claims description 91
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 69
- 150000003839 salts Chemical class 0.000 claims description 69
- 229910052751 metal Inorganic materials 0.000 claims description 44
- 239000002184 metal Substances 0.000 claims description 44
- 150000003891 oxalate salts Chemical class 0.000 claims description 44
- 239000011575 calcium Substances 0.000 claims description 38
- 229910052791 calcium Inorganic materials 0.000 claims description 38
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- -1 Oxalate ions Chemical class 0.000 claims description 17
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 17
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 15
- 239000011707 mineral Substances 0.000 claims description 15
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- 229910052708 sodium Inorganic materials 0.000 claims description 13
- 238000001556 precipitation Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 8
- 150000001450 anions Chemical class 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 230000001376 precipitating effect Effects 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 229940102223 injectable solution Drugs 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 239000002244 precipitate Substances 0.000 description 29
- 235000019441 ethanol Nutrition 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 230000007935 neutral effect Effects 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 235000010755 mineral Nutrition 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000005194 fractionation Methods 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 230000001476 alcoholic effect Effects 0.000 description 7
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 7
- 229940100630 metacresol Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000013078 crystal Substances 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical class [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical class [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 150000004653 carbonic acids Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical class CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002913 oxalic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB33170/77A GB1602439A (en) | 1977-08-08 | 1977-08-08 | Purified heparin |
| GB5204777 | 1977-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH636888A5 true CH636888A5 (fr) | 1983-06-30 |
Family
ID=26261753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH841878A CH636888A5 (fr) | 1977-08-08 | 1978-08-08 | Heparines purifiees et leur preparation. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4652555A (en, 2012) |
| JP (1) | JPS5446809A (en, 2012) |
| AT (1) | AT371713B (en, 2012) |
| AU (1) | AU529432B2 (en, 2012) |
| CA (1) | CA1105453A (en, 2012) |
| CH (1) | CH636888A5 (en, 2012) |
| DE (1) | DE2834702A1 (en, 2012) |
| DK (1) | DK350078A (en, 2012) |
| ES (1) | ES472430A1 (en, 2012) |
| FR (1) | FR2400036A1 (en, 2012) |
| IE (1) | IE47169B1 (en, 2012) |
| IT (1) | IT1192564B (en, 2012) |
| NL (1) | NL7808292A (en, 2012) |
| SE (1) | SE447872B (en, 2012) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2461719A2 (fr) * | 1979-07-20 | 1981-02-06 | Choay Sa | Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir |
| EP0245813B2 (en) * | 1986-05-16 | 2000-03-22 | ITALFARMACO S.p.A. | EDTA-free heparins, heparin fractions and fragments, processes for their preparation and pharmaceutical compositions containing them |
| AR243204A1 (es) * | 1986-11-21 | 1993-07-30 | Ajorca Sa | Un metodo para la depolimerizacion quimica de polisacaridos. |
| SE8702254D0 (sv) * | 1987-05-29 | 1987-05-29 | Kabivitrum Ab | Novel heparin derivatives |
| USRE38743E1 (en) | 1990-06-26 | 2005-06-14 | Aventis Pharma S.A. | Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events |
| JP2001231595A (ja) * | 1999-12-15 | 2001-08-28 | Fuaruko Bio Syst:Kk | 特異的破骨細胞由来酸性ホスファターゼの測定方法 |
| JP4828795B2 (ja) | 2002-03-11 | 2011-11-30 | モメンタ ファーマシューティカルズ インコーポレイテッド | 硫酸化多糖類の分析 |
| US9139876B1 (en) | 2007-05-03 | 2015-09-22 | Momenta Pharmacueticals, Inc. | Method of analyzing a preparation of a low molecular weight heparin |
| AU2009250803A1 (en) * | 2008-05-20 | 2009-11-26 | Crystal Clear Partnership | Separation of polysaccharides by charge density gradient |
| ES2340902B1 (es) * | 2008-07-01 | 2011-05-03 | Laboratorios Farmaceuticos Rovi, S.A. | Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas. |
| US8435795B2 (en) * | 2010-01-19 | 2013-05-07 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
| DK2617737T3 (en) * | 2010-09-14 | 2017-04-03 | Univ Miyazaki | HIGH PURPOSE HEPARIN AND PREPARATION PROCEDURE |
| WO2012115952A1 (en) | 2011-02-21 | 2012-08-30 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135660A (en) * | 1956-11-09 | 1964-06-02 | Riker Laboratories Inc | Method for purifying sulfated carbohydrates with oxidizing agents |
| US3482014A (en) * | 1966-06-29 | 1969-12-02 | Canada Packers Ltd | Orally active heparin and method for making and using same |
| FR2225406A1 (en) * | 1973-04-13 | 1974-11-08 | Choay Sa | Sodium-free heparin salts - by cation exchange of sodium salts, anticoagulants without side-effects |
| CA1042001A (en) * | 1973-04-13 | 1978-11-07 | Choay S.A. | Mixed heparin salts |
-
1978
- 1978-08-08 JP JP9659278A patent/JPS5446809A/ja active Granted
- 1978-08-08 IE IE1616/78A patent/IE47169B1/en not_active IP Right Cessation
- 1978-08-08 ES ES472430A patent/ES472430A1/es not_active Expired
- 1978-08-08 NL NL787808292A patent/NL7808292A/xx not_active Application Discontinuation
- 1978-08-08 AU AU38748/78A patent/AU529432B2/en not_active Expired
- 1978-08-08 IT IT26580/78A patent/IT1192564B/it active
- 1978-08-08 CH CH841878A patent/CH636888A5/fr not_active IP Right Cessation
- 1978-08-08 SE SE7808487A patent/SE447872B/sv not_active IP Right Cessation
- 1978-08-08 DK DK350078A patent/DK350078A/da not_active Application Discontinuation
- 1978-08-08 CA CA308,923A patent/CA1105453A/en not_active Expired
- 1978-08-08 FR FR7823396A patent/FR2400036A1/fr active Granted
- 1978-08-08 AT AT0577078A patent/AT371713B/de not_active IP Right Cessation
- 1978-08-08 DE DE19782834702 patent/DE2834702A1/de active Granted
-
1982
- 1982-12-22 US US06/452,197 patent/US4652555A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AT371713B (de) | 1983-07-25 |
| FR2400036A1 (fr) | 1979-03-09 |
| DK350078A (da) | 1979-02-09 |
| NL7808292A (nl) | 1979-02-12 |
| ATA577078A (de) | 1982-12-15 |
| JPS6129327B2 (en, 2012) | 1986-07-05 |
| JPS5446809A (en) | 1979-04-13 |
| DE2834702A1 (de) | 1979-02-22 |
| SE447872B (sv) | 1986-12-22 |
| DE2834702C2 (en, 2012) | 1988-11-10 |
| IE47169B1 (en) | 1984-01-11 |
| ES472430A1 (es) | 1979-03-16 |
| AU529432B2 (en) | 1983-06-09 |
| FR2400036B1 (en, 2012) | 1980-09-19 |
| AU3874878A (en) | 1980-02-14 |
| CA1105453A (en) | 1981-07-21 |
| IT1192564B (it) | 1988-04-20 |
| IE781616L (en) | 1979-02-08 |
| US4652555A (en) | 1987-03-24 |
| SE7808487L (sv) | 1979-02-09 |
| IT7826580A0 (it) | 1978-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH636888A5 (fr) | Heparines purifiees et leur preparation. | |
| EP0037319B2 (fr) | Mucopolysaccharides possédant des propriétés biologiques, leur préparation et leur application en tant que médicaments | |
| EP0076279B1 (fr) | Procede d'obtention de mucopolysaccarides biologiquement actifs, de purete elevee, par depolymerisation controlee de l'heparine | |
| BE1008163A5 (fr) | Nouveaux oligodesoxyribonucleotides a activite anti-ischemique et leur preparation. | |
| EP1556414B1 (fr) | Melanges d'oligosaccharides derives d'heparine, leur preparation et compositions pharmaceutiques les contenant | |
| EP0116801A1 (fr) | Héparine dépolymérisée et supersulfatée, procédé pour sa préparation et compositions pharmaceutiques en contenant | |
| CH668594A5 (fr) | Preparations parenterales de phenytoine. | |
| FR2505185A1 (fr) | Procede de preparation d'un polysulfate de chondroitine injectable, produit obtenu par ce procede et compositions pharmaceutiques le contenant | |
| JPH0667952B2 (ja) | ショ糖脂肪酸エステル合成反応混合物中の未反応糖の回収方法 | |
| CH626808A5 (en, 2012) | ||
| FR2624881A1 (fr) | Procede de traitement des minerais, en particulier pour l'extraction du tungstene, tungstene et articles en tungstene obtenus a l'aide de ce procede | |
| JP3055565B2 (ja) | シクロデキストリン精製工程 | |
| EP2921471A1 (fr) | Procédé d'extraction de l'acide aconitique à partir de produits issus de l'industrie de la canne à sucre | |
| FR2675806A1 (fr) | Polysaccharides sulfates, procede de preparation, composition pharmaceutique et utilisation. | |
| GB2027728A (en) | Physiologically Acceptable Heparin | |
| BE506950A (en, 2012) | ||
| JPH0751064A (ja) | 液状パパインとその製造法 | |
| JPS61197521A (ja) | ヘパリン製剤 | |
| EP0383645A1 (fr) | Procédé de fabrication du facteur antihémophilique (FVIIIc) ayant une très haute pureté. | |
| FR2495935A1 (fr) | Fractions mucopolysaccharidiques possedant des proprietes biologiques, leur procede de preparation et leur application en tant que medicaments | |
| WO2006064150A1 (fr) | Procede d'obtention de polyphenols naturels stabilises, polyphenols ainsi obtenus et utilisation de ces polyphenols dans le metabolisme des glucides | |
| BE438175A (en, 2012) | ||
| JP2757321B2 (ja) | エラグ酸の精製法 | |
| BE439751A (en, 2012) | ||
| BE420377A (en, 2012) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |